GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE and INCORRECT PRODUCT ADMINISTRATION DURATION

Overview

INCORRECT PRODUCT ADMINISTRATION DURATION is the #16 most commonly reported adverse reaction for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, manufactured by RB Health (US) LLC. There are 199 FDA adverse event reports linking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE to INCORRECT PRODUCT ADMINISTRATION DURATION. This represents approximately 1.5% of all 13,133 adverse event reports for this drug.

Patients taking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE who experience incorrect product administration duration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INCORRECT PRODUCT ADMINISTRATION DURATION is a less commonly reported adverse event for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, but still significant enough to appear in the safety profile.

Other Side Effects of GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

In addition to incorrect product administration duration, the following adverse reactions have been reported for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE:

• DRUG INEFFECTIVE — 921 reports
• DIZZINESS — 833 reports
• DIARRHOEA — 621 reports
• ACCIDENTAL OVERDOSE — 524 reports
• NAUSEA — 501 reports
• OVERDOSE — 381 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 345 reports
• SOMNOLENCE — 292 reports
• FEELING ABNORMAL — 283 reports
• VOMITING — 279 reports

Other Drugs Associated with INCORRECT PRODUCT ADMINISTRATION DURATION

The following drugs have also been linked to incorrect product administration duration in FDA adverse event reports:

Does GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE cause INCORRECT PRODUCT ADMINISTRATION DURATION?

INCORRECT PRODUCT ADMINISTRATION DURATION has been reported as an adverse event in 199 FDA reports for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INCORRECT PRODUCT ADMINISTRATION DURATION with GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?

INCORRECT PRODUCT ADMINISTRATION DURATION accounts for approximately 1.5% of all adverse event reports for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, making it a notable side effect.

What should I do if I experience INCORRECT PRODUCT ADMINISTRATION DURATION while taking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?

If you experience incorrect product administration duration while taking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages